Header

News archive

Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.

Showing 14 results

April 2023

Pulse UpdateApr 21, 2023
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®

March 2023

Pulse UpdateMar 02, 2023
Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch

January 2023

Pulse UpdateJan 09, 2023
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023

December 2021

Pulse UpdateDec 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease

September 2021

August 2021

July 2021

June 2021

Pulse UpdateJun 16, 2021
Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)